HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Conditions
- Myelodysplastic Syndrome (MDS)
- Chronic Lymphocytic Leukemia (CLL)
- Chemotherapy-sensitive Lymphoma
- Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma
- Acute Myelogenous Leukemia (AML)
- Acute Biphenotypic Leukemia (ABL)
- Acute Undifferentiated Leukemia (AUL)
Interventions
- DRUG: Fludarabine
- DRUG: Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5
- RADIATION: Total Body Irradiation (TBI) 200cGy on Day -1
- PROCEDURE: Infusion of non-T-cell depleted bone marrow on Day 0
- DRUG: Busulfan
- DRUG: Cyclophosphamide 50mg/kg/day IV on Days -2,-1
- DRUG: Cyclophosphamide 50mg/kg/day IV on Days -5,-4
- RADIATION: Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1
- DRUG: Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4
- DRUG: Sirolimus
- DRUG: Mycophenolate mofetil
- DRUG: G-CSF
- DRUG: Pre-HCT Mesna on Days -6 and -5
- DRUG: Pre-HCT Mesna on Days -2 and -1
- DRUG: Pre-HCT Mesna on Days -5 and -4
- DRUG: Post-HCT Mesna
Sponsor
Center for International Blood and Marrow Transplant Research
Collaborators